JP2022046811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022046811A5 JP2022046811A5 JP2022006917A JP2022006917A JP2022046811A5 JP 2022046811 A5 JP2022046811 A5 JP 2022046811A5 JP 2022006917 A JP2022006917 A JP 2022006917A JP 2022006917 A JP2022006917 A JP 2022006917A JP 2022046811 A5 JP2022046811 A5 JP 2022046811A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- subject
- medicament
- peptide
- heart failure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 230000002107 myocardial effect Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 230000008828 contractile function Effects 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 241000208011 Digitalis Species 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 229940123457 Free radical scavenger Drugs 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 102000003938 Thromboxane Receptors Human genes 0.000 claims 1
- 108090000300 Thromboxane Receptors Proteins 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000003257 anti-anginal effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 231100000457 cardiotoxic Toxicity 0.000 claims 1
- 230000001451 cardiotoxic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 230000000297 inotrophic effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24868109P | 2009-10-05 | 2009-10-05 | |
| US61/248,681 | 2009-10-05 | ||
| US28948309P | 2009-12-23 | 2009-12-23 | |
| US61/289,483 | 2009-12-23 | ||
| JP2020030241A JP7017762B2 (ja) | 2009-10-05 | 2020-02-26 | 心不全の予防又は処置の方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020030241A Division JP7017762B2 (ja) | 2009-10-05 | 2020-02-26 | 心不全の予防又は処置の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022046811A JP2022046811A (ja) | 2022-03-23 |
| JP2022046811A5 true JP2022046811A5 (https=) | 2022-12-12 |
| JP7382607B2 JP7382607B2 (ja) | 2023-11-17 |
Family
ID=43823652
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532388A Pending JP2013506696A (ja) | 2009-10-05 | 2010-10-04 | 心不全の予防又は処置の方法 |
| JP2015050464A Pending JP2015163609A (ja) | 2009-10-05 | 2015-03-13 | 心不全の予防又は処置の方法 |
| JP2016156631A Active JP6429835B2 (ja) | 2009-10-05 | 2016-08-09 | 心不全の予防又は処置の方法 |
| JP2018165223A Pending JP2018203764A (ja) | 2009-10-05 | 2018-09-04 | 心不全の予防又は処置の方法 |
| JP2020030241A Active JP7017762B2 (ja) | 2009-10-05 | 2020-02-26 | 心不全の予防又は処置の方法 |
| JP2022006917A Active JP7382607B2 (ja) | 2009-10-05 | 2022-01-20 | 心不全の予防又は処置の方法 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532388A Pending JP2013506696A (ja) | 2009-10-05 | 2010-10-04 | 心不全の予防又は処置の方法 |
| JP2015050464A Pending JP2015163609A (ja) | 2009-10-05 | 2015-03-13 | 心不全の予防又は処置の方法 |
| JP2016156631A Active JP6429835B2 (ja) | 2009-10-05 | 2016-08-09 | 心不全の予防又は処置の方法 |
| JP2018165223A Pending JP2018203764A (ja) | 2009-10-05 | 2018-09-04 | 心不全の予防又は処置の方法 |
| JP2020030241A Active JP7017762B2 (ja) | 2009-10-05 | 2020-02-26 | 心不全の予防又は処置の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US20110082084A1 (https=) |
| EP (5) | EP2485749A4 (https=) |
| JP (6) | JP2013506696A (https=) |
| CN (2) | CN102711785A (https=) |
| CA (1) | CA2776581C (https=) |
| HK (1) | HK1217293A1 (https=) |
| WO (1) | WO2011044044A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9306796B1 (en) | 2008-03-18 | 2016-04-05 | Mcafee, Inc. | System, method, and computer program product for dynamically configuring a virtual environment for identifying unwanted data |
| CN105031605A (zh) * | 2009-08-12 | 2015-11-11 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
| EP2485749A4 (en) | 2009-10-05 | 2013-07-24 | Univ Cornell | METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE |
| EP3266462A1 (en) * | 2009-12-31 | 2018-01-10 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
| JP6317324B2 (ja) * | 2012-03-30 | 2018-04-25 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 神経障害を予防および処置するための方法および組成物 |
| AU2013334788A1 (en) * | 2012-10-22 | 2015-06-04 | Henry Ford Health Systems | Methods for reducing risks associated with heart failure and factors associated therewith |
| CN110339339A (zh) * | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
| EP3626252A1 (en) * | 2013-03-01 | 2020-03-25 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| CA2912386A1 (en) * | 2013-05-14 | 2014-11-20 | Stealth Biotherapeutics Corp | Methods for the prevention or treatment of left ventricular remodeling |
| JP2016520130A (ja) * | 2013-05-28 | 2016-07-11 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 心臓疾患における新規治療戦略としてのｂｅｔ阻害 |
| US10047395B2 (en) * | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| WO2015017861A1 (en) * | 2013-08-02 | 2015-02-05 | Stealth Peptides International, Inc. | Methods and compositions for the prevention and treatment of friedreich's ataxia |
| WO2016004441A1 (en) * | 2014-07-03 | 2016-01-07 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of acute myocardial infarction injury |
| US10368774B2 (en) * | 2015-07-30 | 2019-08-06 | Medtronic, Inc. | Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event |
| CA3010599C (en) * | 2016-01-06 | 2025-05-20 | Stealth Biotherapeutics Inc. | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY |
| WO2017151886A1 (en) * | 2016-03-02 | 2017-09-08 | Stealth Biotherapeutics Corp | Methods and compositions for the treatment and prevention of pulmonary arterial hypertension |
| CA3020393A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| US11865162B2 (en) | 2016-07-01 | 2024-01-09 | Marshall University Research Corporation | Compositions and methods for treatment of uremic cardiomyopathy |
| CA3060985A1 (en) | 2017-04-21 | 2018-10-25 | Northeast Ohio Medical University | Vasodilators for treatment of heart failure |
| WO2020118035A1 (en) * | 2018-12-06 | 2020-06-11 | Stealth Biotherapeutics Corp | Methods and compositions for the treatment of sengers syndrome |
| CN112111003B (zh) * | 2019-06-20 | 2022-02-11 | 中国农业大学 | 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽 |
| EP3771467A1 (en) | 2019-07-30 | 2021-02-03 | Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau | Ss-31 for the prevention and/or treatment of aneurysm |
| US20230256047A1 (en) * | 2020-06-17 | 2023-08-17 | Stealth Biotherapeutics Inc. | Methods and compositions for the treatment of muscular dystrophy |
| CA3191819A1 (en) | 2020-09-09 | 2022-03-17 | Hazel Szeto | Methods and compositions for delivery of biotin to mitochondria |
| CN117881411A (zh) | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
| CN117384253A (zh) * | 2023-08-28 | 2024-01-12 | 南京医科大学 | 一类肽及其衍生物和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4732898A (en) * | 1986-04-29 | 1988-03-22 | Warner-Lambert Company | 2-(2-aryl-2-oxoalkylidene) analogs of-3,5-pyridinedicarboxylic acid dialkyl esters useful for treatment of cardiovascular disorders |
| US5602100A (en) * | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
| EP0350221B1 (en) * | 1988-06-30 | 1996-04-17 | Astra Aktiebolag | Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same |
| US5670617A (en) * | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) * | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| ATE255450T1 (de) * | 1995-06-09 | 2003-12-15 | Hisamitsu Pharmaceutical Co | Matrix für iontophorese |
| US5849761A (en) * | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
| WO1997016169A1 (en) * | 1995-11-01 | 1997-05-09 | Chiron Corporation | Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
| US5885958A (en) * | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
| US6489300B1 (en) * | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| CA2314267A1 (en) * | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| JP2002512954A (ja) * | 1998-04-24 | 2002-05-08 | マイトコー | ミトコンドリア関連疾患を処置するための化合物および方法 |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| SE9900961D0 (sv) * | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
| AU7855900A (en) * | 1999-10-04 | 2001-05-10 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying rna binding compounds |
| US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
| US20050192215A1 (en) * | 2000-01-21 | 2005-09-01 | Malabika Ghosh | Methods and materials relating to novel polypeptides and polynucleotides |
| EP1303186B1 (en) * | 2000-07-18 | 2011-01-26 | Cornell Research Foundation, Inc. | Medicinal uses of mu-opioid receptor agonists |
| US6900178B2 (en) | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
| IT1318370B1 (it) * | 2000-12-21 | 2003-08-25 | Tonino Bombardini | Metodo e dispositivo per la diagnosi e la terapia dello scompensocardiaco cronico. |
| US20070015146A1 (en) * | 2001-05-22 | 2007-01-18 | Gene Logic, Inc. | Molecular nephrotoxicology modeling |
| US7320959B2 (en) * | 2001-10-01 | 2008-01-22 | Vanderbilt University | Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease |
| US7776925B2 (en) * | 2002-03-06 | 2010-08-17 | Duke University | Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria |
| SI2656854T1 (sl) * | 2003-02-04 | 2015-09-30 | Cornell Research Foundation, Inc. | Uporabe aromatsko-kationskega peptida |
| JP4879020B2 (ja) * | 2003-05-01 | 2012-02-15 | コーネル リサーチ ファウンデイション インコーポレイテッド | 細胞に分子を送達する方法及び担体複合体 |
| US7232824B2 (en) * | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
| CA2851972C (en) * | 2004-01-23 | 2015-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
| CA2947335A1 (en) * | 2005-09-16 | 2007-03-29 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
| US20070259377A1 (en) * | 2005-10-11 | 2007-11-08 | Mickey Urdea | Diabetes-associated markers and methods of use thereof |
| US20080027082A1 (en) * | 2006-06-19 | 2008-01-31 | Berthold Hocher | Use of adenosine a1 antagonists in radiocontrast media induced nephropathy |
| EP3103467A1 (en) * | 2008-02-07 | 2016-12-14 | Cornell University | Methods for preventing or treating insulin resistance |
| DK2262520T3 (en) | 2008-02-26 | 2017-08-07 | Univ Cornell | COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury |
| EP3563862B1 (en) | 2009-03-20 | 2021-05-05 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries |
| CN105031605A (zh) * | 2009-08-12 | 2015-11-11 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
| EP2485749A4 (en) | 2009-10-05 | 2013-07-24 | Univ Cornell | METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE |
| WO2011151359A1 (en) * | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
-
2010
- 2010-10-04 EP EP10822481.7A patent/EP2485749A4/en not_active Withdrawn
- 2010-10-04 EP EP16169795.8A patent/EP3120860B1/en active Active
- 2010-10-04 CN CN2010800551907A patent/CN102711785A/zh active Pending
- 2010-10-04 CA CA2776581A patent/CA2776581C/en active Active
- 2010-10-04 EP EP15154763.5A patent/EP2944317A1/en not_active Withdrawn
- 2010-10-04 WO PCT/US2010/051329 patent/WO2011044044A1/en not_active Ceased
- 2010-10-04 CN CN201410049107.5A patent/CN103845724A/zh active Pending
- 2010-10-04 EP EP14151500.7A patent/EP2764871A1/en not_active Withdrawn
- 2010-10-04 JP JP2012532388A patent/JP2013506696A/ja active Pending
- 2010-10-04 US US12/897,325 patent/US20110082084A1/en not_active Abandoned
- 2010-10-04 EP EP19175034.8A patent/EP3603658B1/en active Active
-
2013
- 2013-09-24 US US14/035,577 patent/US20140100166A1/en not_active Abandoned
-
2015
- 2015-03-13 JP JP2015050464A patent/JP2015163609A/ja active Pending
- 2015-06-01 US US14/727,513 patent/US20160106800A1/en not_active Abandoned
-
2016
- 2016-05-10 HK HK16105288.2A patent/HK1217293A1/en unknown
- 2016-08-09 JP JP2016156631A patent/JP6429835B2/ja active Active
-
2017
- 2017-10-03 US US15/723,259 patent/US20180236025A1/en not_active Abandoned
-
2018
- 2018-09-04 JP JP2018165223A patent/JP2018203764A/ja active Pending
-
2020
- 2020-02-20 US US16/796,940 patent/US11534476B2/en active Active
- 2020-02-26 JP JP2020030241A patent/JP7017762B2/ja active Active
- 2020-10-29 US US17/084,046 patent/US20210187056A1/en not_active Abandoned
-
2022
- 2022-01-20 JP JP2022006917A patent/JP7382607B2/ja active Active
- 2022-12-12 US US18/079,604 patent/US12102659B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022046811A5 (https=) | ||
| JP2013506696A5 (https=) | ||
| Momma | ACE inhibitors in pediatric patients with heart failure | |
| Anderson et al. | Cardiovascular complications of malignant carcinoid disease | |
| JP2022116008A5 (https=) | ||
| JP2003507418A5 (https=) | ||
| JP2016522196A5 (https=) | ||
| JP2016503397A5 (https=) | ||
| Plosker et al. | Quinapril: a reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders | |
| JP2021530517A5 (https=) | ||
| US6013678A (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
| JP2004536834A5 (https=) | ||
| Zannad | Clinical pharmacology of nisoldipine coat core | |
| RU2245712C2 (ru) | Применение антагонистов кортизола при лечении сердечной недостаточности | |
| Gomez et al. | Enalapril in congestive heart failure: acute and chronic invasive hemodynamic evaluation | |
| AU766230B2 (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
| Vyssoulis et al. | Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients | |
| Somani et al. | Clinical indications for calcium channel blockers | |
| Massie et al. | Acute and long-term effects of captopril on left and right ventricular volumes and function in chronic heart failure | |
| Landau et al. | Calcium antagonists for the treatment of congestive heart failure | |
| Anjaneyulu et al. | Acute reversible left ventricular dysfunction following general anesthesia | |
| Takahashi et al. | Allergic granulomatosis and angiitis with severe cardiac disease: a case in which cardiac function was extremely improved by long-term steroid therapy | |
| Kikuchi et al. | Marked and prompt hemodynamic improvement by carperitide in refractory congestive heart failure due to dilated cardiomyopathy | |
| CA2387920C (en) | A new use of levosimendan | |
| Checchia et al. | Current concepts in the recognition and management of pediatric cardiogenic shock and congestive heart failure |